● SNPS
· FINANCIAL METRICS · Oct 2016 — Oct 2025
Financial overview
10 reporting periods tracked across income statement, balance sheet, and cash flow data.
Net Revenue $7.1B +15.1% YoY
Net Income $1.0M +103.7% YoY
Operating Income $914.9M -32.5% YoY
Total Assets $1.2B +5.1% YoY
● FINANCIAL STATEMENTS
The numbers, in full.
| $ millions | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Accounts receivable (less allowance for credit losses of $30 and $27, respectively) | 438.9M | 451.1M +2.8% | 554.2M +22.9% | 553.9M -0.1% | 780.7M +41.0% | 568.5M -27.2% | 796.1M +40.0% | 947.0M +18.9% | 934.5M -1.3% | 1.5B +61.1% |
| Net sales | - | - | - | - | - | 4.2B | 5.1B +20.9% | 5.8B +15.0% | 6.1B +4.9% | 7.1B +15.1% |
| Amortization of intangible assets | - | - | - | - | - | 48.5M | 66.9M +38.1% | 74.9M +11.8% | 108.0M +44.3% | 311.9M +188.8% |
| COST OF GOODS SOLD | - | - | - | - | - | 861.8M | 1.1B +23.4% | 1.2B +14.9% | 1.2B +1.9% | 1.6B +30.4% |
| Gross profit | - | - | - | - | - | 3.3B | 4.0B +20.2% | 4.6B +15.0% | 4.9B +5.7% | 5.4B +11.2% |
| Research and development | - | - | - | - | - | 1.5B | 1.7B +11.7% | 1.9B +15.9% | 2.1B +7.0% | 2.5B +19.1% |
| Sales and marketing | - | - | - | - | - | 712.5M | 779.8M +9.4% | 889.0M +14.0% | 859.3M -3.3% | 1.1B +25.0% |
| General and administrative | - | - | - | - | - | 323.0M | 353.8M +9.6% | 410.3M +16.0% | 568.5M +38.5% | 769.6M +35.4% |
| Amortization of excess cost of equity investments | - | - | - | - | - | 33.9M | 29.8M -12.3% | 28.0M -5.8% | - | - |
| Restructuring | - | - | - | - | - | 33.4M | 12.1M -63.9% | 77.0M +538.6% | - | - |
| Total operating expenses | - | - | - | - | - | 2.6B | 2.9B +9.5% | 3.4B +17.4% | 3.5B +5.2% | 4.5B +28.1% |
| Operating earnings | - | - | - | - | - | 734.8M | 1.2B +58.1% | 1.3B +9.2% | 1.4B +6.8% | 914.9M -32.5% |
| Total other expense – net | - | - | - | - | - | 70.7M | -46.5M -165.8% | 32.5M +169.9% | 158.1M +386.3% | 924.9M +484.9% |
| Earnings before income taxes | - | - | - | - | - | 805.5M | 1.1B +38.5% | 1.3B +16.7% | 1.5B +16.3% | 1.4B -8.0% |
| Income tax provision | - | - | - | - | - | 49.2M | 137.1M +178.9% | 83.7M -39.0% | 99.7M +19.2% | 56.0M -43.9% |
| Net earnings | - | - | - | - | - | 756.4M | 978.4M +29.4% | 1.2B +24.5% | 2.2B +83.5% | 1.3B -40.4% |
| Less: Net earnings attributable to noncontrolling interest | - | - | - | - | - | -1.2M | -6.2M -432.2% | -11.8M -91.0% | -27.6M -134.4% | 1.0M +103.7% |
| Net earnings attributable to W.W. Grainger, Inc. | - | - | - | - | - | 757.5M | 984.6M +30.0% | 1.2B +24.9% | 2.3B +84.0% | 1.3B -41.1% |
| Basic (in dollars per share) | - | - | - | - | - | 4.96 | 6.44 +29.8% | 8.08 +25.5% | 14.78 +82.9% | 8.13 -45.0% |
| Diluted (in dollars per share) | - | - | - | - | - | 4.81 | 6.29 +30.8% | 7.92 +25.9% | 14.51 +83.2% | 8.04 -44.6% |
| Basic (in shares) | - | - | - | - | - | 152.7M | 153.0M +0.2% | 152.1M -0.6% | 153.1M +0.7% | 163.9M +7.1% |
| Diluted (in shares) | - | - | - | - | - | 157.3M | 156.5M -0.5% | 155.2M -0.8% | 155.9M +0.5% | 165.7M +6.2% |
| Depreciation and amortization | - | - | - | - | - | 203.7M | 228.4M +12.1% | 247.1M +8.2% | 295.1M +19.4% | 660.4M +123.8% |
| Provision for credit losses | - | - | - | - | - | 18.5M | -3.5M -118.8% | 19.9M +673.3% | 19.7M -1.0% | 50.9M +158.0% |
| Amortization of intangible assets | - | - | - | - | - | - | - | - | 16.2M | 192.5M +1085.6% |
| Net income from continuing operations before allocation to noncontrolling interests | - | - | - | - | - | - | - | - | 1.4B | 1.3B -5.4% |
| Discontinued operations––net of tax | - | - | - | - | - | - | - | - | 821.7M | -3.9M -100.5% |
| Income from continuing operations | - | - | - | - | - | - | - | - | 1.4B | 1.3B -7.3% |
| Income from discontinued operations | - | - | - | - | - | - | - | - | 821.7M | -3.9M -100.5% |
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | - | - | - | - | - | - | - | - | 9.41 | 8.15 -13.4% |
| Discontinued operations––net of tax (in dollars per share) | - | - | - | - | - | - | - | - | 5.37 | -0.02 -100.4% |
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | - | - | - | - | - | - | - | - | 9.25 | 8.07 -12.8% |
| Discontinued operations––net of tax (in dollars per share) | - | - | - | - | - | - | - | - | 5.26 | -0.03 -100.6% |
| Gain related to merger of businesses | - | - | - | - | - | - | - | - | 868.8M | 508.0M -41.5% |
| Amortization of debt issuance costs | - | - | - | - | - | - | - | - | 33.7M | - |
| Interest expense – net | - | - | - | - | - | - | - | - | - | 446.7M |
| Loss on sale of premises and equipment, net | - | - | - | - | - | - | - | - | - | 51.4M |
| Change in fair market value of derivative contracts | - | - | - | - | - | - | - | - | - | 121.6M |
Source: SEC Form 10-K + 10-Q · GAAP Latest filing: Dec 15, 2020